Juniper Genomics

Embryome Inc. , trading under the name Juniper Genomics is a biotechnology company that specializes in enhancing in vitro fertilization (IVF) outcomes through innovative genomic technologies. Their sophisticated data analysis improves embryo selection for higher success rates in fertility treatments. Juniper Genomics develops advanced genomic solutions aimed at improving IVF processes.

In June 2025, Juniper Genomics raised USD 4. 6 million in seed funding led by new investor Company Ventures, with participation from other new investors Innospark Ventures, MBX Capital, Amboy Street Ventures, and Dria Ventures. Returning investor Blue Collective also participated in the round. Juniper Genomics specializes in advanced solutions for in vitro fertilization (IVF) through its proprietary technology that leverages whole genome and transcriptome sequencing alongside sophisticated data analysis.

The company's core offerings center around enhancing embryo selection accuracy to ensure a higher likelihood of success for fertility treatments. By collecting extensive input data, including DNA, RNA, and parental information, Juniper Genomics processes and analyzes this data to create a rich dataset focused on IVF outcomes. This integration of data into a sophisticated algorithm enables clinicians to select the most viable embryo for transfer, significantly reducing the emotional and financial burden associated with IVF procedures. Juniper Genomics primarily serves fertility clinics and aspiring parents, operating in North America and Europe, where its technology is designed to improve the chances of a successful conception on the first embryo transfer.

Juniper Genomics operates on a revenue model that includes partnerships with fertility clinics and direct services to patients undergoing IVF treatments. The company’s offerings focus on improving embryo viability through scientific validation in transaction structures that favor B2B engagements with reproductive health specialists. The service model involves one-time fees or subscription arrangements for ongoing analysis and support, providing clinics access to Juniper's technology. As these clinics integrate Juniper's solutions into their workflows, it bolsters their service offerings while potentially enhancing patient outcomes.

The core product, which focuses on embryo selection based on robust genetic data, positions Juniper Genomics in the reproductive health market. The company will use the June 2025 funding for team growth and expand its market reach across North America.